Literature DB >> 25849120

Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients.

Xiangsheng Xu1, Qinghua Shang2, Xinyue Chen3, Weimin Nie4, Zhengsheng Zou5, Ang Huang5, Ming Meng6, Lei Jin7, Ruonan Xu7, Ji-Yuan Zhang7, Junliang Fu7, Lifeng Wang7, Zirong Tang7, Yunbo Xie7, Xiaoming Yang8, Zheng Zhang7, Fu-Sheng Wang7.   

Abstract

B cells play an important role in the clearance of hepatitis B virus (HBV) and protection against reinfection. However, the functional characteristics of these cells that are associated with the outcome of chronic HBV infection remain unknown. We comprehensively investigated the frequency, phenotype, and function of peripheral B-cell subsets from CHB patients in different phases: immune tolerance (IT), immune activation (IA), immune clearance (IC), responders with HBsAg seroconversion (resolved patients, RP), and healthy controls (HC). IA patients displayed lower percentages of peripheral blood memory B cells compared with the other groups. Overall polyclonal activation of B cells, indicated by higher levels of activation markers and secretion of IgG and IgM, was observed in IA patients. This B-cell hyperactivation could be induced by increased IFN-α and soluble CD40 ligands in IA patients. Notably, the expression of the co-stimulator molecule CD80 and serum HBsAb and the frequency of HBsAg-specific B cells were significantly decreased in IT, IA, and IC patients compared with HC subjects. More importantly, the B-cell hyperactivation, co-stimulatory molecule downregulation and HBsAg-specific B-cell impairment were reversed in RP patients. The reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25849120      PMCID: PMC4654326          DOI: 10.1038/cmi.2015.25

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  36 in total

1.  Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.

Authors:  I Dervite; D Hober; P Morel
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

2.  Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection.

Authors:  W O Böcher; S Herzog-Hauff; W Herr; K Heermann; G Gerken; K H Meyer Zum Büschenfelde; H F Löhr
Journal:  Clin Exp Immunol       Date:  1996-07       Impact factor: 4.330

3.  Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.

Authors:  P Niscola; M I Del Principe; L Maurillo; A Venditti; F Buccisano; D Piccioni; S Amadori; G Del Poeta
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

Review 4.  Flying under the radar: the immunobiology of hepatitis C.

Authors:  Lynn B Dustin; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors.

Authors:  Ying Luo; Chung Mau Lo; Cindy K Cheung; George K Lau; Sheung Tat Fan; John Wong
Journal:  Liver Transpl       Date:  2007-01       Impact factor: 5.799

6.  Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors:  J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

Authors:  C Boni; A Penna; G S Ogg; A Bertoletti; M Pilli; C Cavallo; A Cavalli; S Urbani; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

8.  B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B.

Authors:  Liangen Chen; Zheng Zhang; Weiwei Chen; Zhidong Zhang; Yonggang Li; Ming Shi; Jiyuan Zhang; Lieping Chen; Shengdian Wang; Fu-Sheng Wang
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

9.  Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B.

Authors:  Chung-Mau Lo; James Tak-Kwan Fung; George Ka-Kit Lau; Chi-Leung Liu; Siu-Tim Cheung; Ching-Lung Lai; Sheung-Tat Fan; John Wong
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

10.  The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.

Authors:  M K Maini; C Boni; C K Lee; J R Larrubia; S Reignat; G S Ogg; A S King; J Herberg; R Gilson; A Alisa; R Williams; D Vergani; N V Naoumov; C Ferrari; A Bertoletti
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

View more
  30 in total

Review 1.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

2.  Overview of the special issue on HBV immunity.

Authors:  Antonio Bertoletti; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

Review 3.  Humoral immunity, the underestimated player in hepatitis B.

Authors:  Shuye Zhang; Juanjuan Zhao; Zheng Zhang
Journal:  Cell Mol Immunol       Date:  2017-12-11       Impact factor: 11.530

Review 4.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 5.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 6.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection.

Authors:  Li Wang; Kai Wang; Zhi-Qiang Zou
Journal:  World J Hepatol       Date:  2015-12-28

7.  PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Authors:  Loghman Salimzadeh; Nina Le Bert; Charles-A Dutertre; Upkar S Gill; Evan W Newell; Christian Frey; Magdeleine Hung; Nikolai Novikov; Simon Fletcher; Patrick Tf Kennedy; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2018-08-07       Impact factor: 14.808

8.  Entering the spotlight: hepatitis B surface antigen-specific B cells.

Authors:  Christoph Neumann-Haefelin; Robert Thimme
Journal:  J Clin Invest       Date:  2018-09-17       Impact factor: 14.808

Review 9.  Immunobiology and pathogenesis of hepatitis B virus infection.

Authors:  Matteo Iannacone; Luca G Guidotti
Journal:  Nat Rev Immunol       Date:  2021-05-17       Impact factor: 53.106

Review 10.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.

Authors:  Arshi Khanam; Joel V Chua; Shyam Kottilil
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.